Orphazyme A/S ADR (ORPH) Social Stream



Orphazyme A/S ADR (ORPH): $0.87

0.02 (-2.25%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add ORPH to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#199 of 414

in industry

Orphazyme A (ORPH) Price Targets From Analysts

Use the tables below to see what analysts covering Orphazyme A think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-02-23 3 $1 $1 $1 $0.87 14.94%
2022-03-11 2 $1 $1 $1 $0.87 14.94%

Over the past 164 days, ORPH's average upside potential has been -32.76%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-09-28 3 1 1 1 4.210 -76.25%
2022-02-23 3 1 1 1 2.020 -50.5%
2022-02-23 2 1 1 1 2.020 -50.5%
2022-03-11 2 1 1 1 0.684 46.2%

ORPH Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
4.5 0 0 0 1 1 2

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ORPH as an investment opportunity.

  • Orphazyme A's variance in analysts' estimates is lower than nearly 100% of all US stocks.
  • In terms of how Orphazyme A fares relative to all US stocks, note that its average analyst price target is higher than 0.1% of that group.
  • Orphazyme A's upside potential (average analyst target price relative to current price) is greater than 16.7% of Pharmaceutical Products stocks.
  • Orphazyme A's number of analysts covering the stock is greater than 16.99% of Healthcare stocks.

Stocks similar to Orphazyme A in the Pharmaceutical Products industry regarding analyst recommendations and price targets are ORMP, ORIC, and OPTN.

Make investment decisions regarding ORPH using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!